SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
Gareth J. Inman(Cancer Research UK), Francisco José Nicolás(GlaxoSmithKline (United States)), James F. Callahan(GlaxoSmithKline (United States)), John D. Harling(Cancer Research UK), Laramie M. Gaster(GlaxoSmithKline (United Kingdom)), Alastair D. Reith(GlaxoSmithKline (United States)), Nicholas J. Laping(Cancer Research UK), Caroline S. Hill(Cancer Research UK)
Cited by 1,653
Abstract
Related Papers
No related papers found
Powered by citation graph analysis